Close Menu

financial guidance

Organically, the diagnostics segment was up 14 percent. Overall, the company's revenues grew 18 percent year over year during the quarter.

Within diagnostics, the firm posted molecular diagnostics revenues of $164.3 million, up 11 percent from $148.6 million in fiscal Q1 2018.

The firm has initiated measures to sharpen its focus on the business success of its Atellica Solution, which consists of immunoassay and chemistry analyzers.

Alere rapid diagnostics revenues were $548 million in the quarter, driven by infectious disease and cardiometabolic testing product sales.

The firm also reaffirmed its previous guidance of 10 percent growth for fiscal 2019.

Among the updates provided Wednesday, Quidel's CEO noted the firm's growing presence in point-of-care markets, while PerkinElmer discussed plans for its Vanadis test.


The firm's CEO told investors at the JP Morgan Healthcare Conference that in addition to driving growth of its sepsis test in the US, Accelerate is eyeing expansion into China.

The firm also posted full-year revenue growth of approximately 3 percent to $315 million, near the top end of its guidance of $310 million to $316 million and above analysts' consensus estimate.

The company also reaffirmed fiscal fourth quarter growth expectations including double-digit growth in the US for its TB testing products.

The company also reaffirmed its guidance for the fourth quarter, and continues to expect revenues of $46.5 million to $48.0 million and EPS of $.09 to $.11.

Pages